succinate

ALK2-IN-4 succinate is a potent and effective inhibitor of ALK2 (ActRI), providing significant promise for therapeutic uses [ActR-1].

Hydrocortisone sodium succinate (Hydrocortisone sodium succinate) , as a glucocorticoid, is an orally active steroidal anti-inflammatory agent (SAID) with both anti-inflammatory and immunomodulatory functions. It inhibits the biological activities of IL-6 and IL-3, with IC50 values of 6.7 μM and 21.4 μM, respectively. Hydrocortisone sodium succinate is also used in research related to ulcerative colitis (UC) and recurrent aphthous ulcers.

Lanraplenib succinate inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans. Lanraplenib succinate is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases.

PF-0463481 succinate is a potent and orally active dual antagonist of CCR2/CCR5, exhibiting comparable human and rodent CCR2 potency with an IC50 of 20.8 nM.

Ribociclib succinate hydrate is a highly specific CDK4/6 inhibitor (IC50s: 10 nM and 39 nM, respectively). It also is over 1,000-fold less potent against the cyclin B/CDK1 complex.

MK-0812 Succinate is an effective and selective CCR2 antagonist. It also has a high affinity at CCR2.

m-PEG-Succinimidyl Succinate (MW 5000) is a polyethylene glycol (PEG)-based linker with succinimidyl succinate functionality, mainly used in the synthesis of proteolysis-targeting chimeras (PROTACs)[1].

Succinate dehydrogenase-IN-4 (Compound 4b) is an inhibitor of succinate dehydrogenase with an IC50 value of 3.38 μM. It exhibits antifungal activity against Physalospora piricola and Colletotrichum orbiculare, with EC50 values of 16.33 μM and 18.06 μM, respectively.

Succinate dehydrogenase-IN-5 (Compound M8) acts as an inhibitor of succinate dehydrogenase. It disrupts energy metabolism and growth in fungi and is effective against Rhizoctonia solani, Sclerotinia sclerotiorum, Botrytis cinerea, and Fusarium graminearum, with an EC50 of less than 0.3 μg/mL.

Succinate dehydrogenase-IN-7 (Compound 2f) is a succinate dehydrogenase inhibitor with an IC50 value of 2.51 μM and exhibits bactericidal properties.

Succinate dehydrogenase-IN-6 (Compound E23) is an inhibitor of succinate dehydrogenase (SDH), effectively hindering SDH in Rhizoctonia solani with an IC50 of 11.76 μM. This compound disrupts fungal cell membranes and exhibits broad-spectrum antifungal activity, capable of inhibiting R. solani, V. dahliae, A. solani, and C. gloeosporioides with EC50 values of 0.41, 0.27, 1.15, and 0.27 μg/mL, respectively. Furthermore, Succinate dehydrogenase-IN-6 shows no significant toxicity in rice and zebrafish (LC50 > 12.5 μg/mL).

Succinate dehydrogenase-IN-9 (Compound Iik) is an inhibitor of succinate dehydrogenase with an IC50 of 3.6 μM. It demonstrates strong inhibitory activity against various fungi, such as S. sclerotiorum, with an EC50 of 1.14 μg/mL. Additionally, Succinate dehydrogenase-IN-9 enhances nitrate reductase activity, promoting plant growth.

Succinate dehydrogenase-IN-8 (compound i19) is a potent inhibitor of succinate dehydrogenase (SDH). This indanoyl amino acid derivative demonstrates strong antifungal activity in vitro against Rhizoctonia solani (EC50 = 0.1843 mg/L), Botrytis cinerea (EC50 = 0.4829 mg/L), and Sclerotinia sclerotiorum (EC50 = 0.1349 mg/L).

Paclitaxel-2′-succinate NHS ester is a derivative of paclitaxel featuring a succinate linker with its carboxyl group activated as an NHS ester. The NHS ester moiety exhibits high reactivity towards amino or hydroxyl groups, facilitating its conjugation with various molecules (such as peptides, proteins, antibodies, enzymes, or polymers). This compound is utilized in the development of nanomedicines and cancer research.

Succinate dehydrogenase-IN-10 (Compound B5) is an inhibitor of RsSDH (Succinate dehydrogenase in R. solani) with an IC50 of 0.12 μM. It exhibits antifungal activity against R. solani with an EC50 of 0.002 μg/mL and also shows efficacy against P. pachyrhizi.

Succinate dehydrogenase-IN-11 (Compound A12) is an inhibitor of succinate dehydrogenase with an IC50 of 3.58 μM. It demonstrates antifungal activity and is effective in vitro against R. solani, B. cinerea, F. graminearum, and S. sclerotiorum. In vivo, it shows efficacy against R. solani, P. pachyrhizi, and P. sorghi, making it suitable for antifungal research.

Prednisolone (sodium succinate) is a corticosteroid with anti-inflammatory properties and serves as a prodrug of the glucocorticoid prednisolone. It can also function as an immunosuppressant.

Iron(II) succinate (Ferrous succinate) is a ferrous salt containing iron and is used as an iron supplement.

Frovatriptan Succinate is a synthetic triptan with 5-HT1B/1D receptors agonist activity. It is indicated for the acute treatment of migraine.

Succinate calcium is a crucial intermediate in the citric acid cycle (tricarboxylic acid cycle). It serves as a specific ligand for the G protein-coupled receptor GPR91. Additionally, succinate calcium can enhance the amplitude of calcium transients in cardiomyocytes and expedite their decay. Furthermore, it can induce myocardial apoptosis (apoptosis).

Betamethasonesuccinate (NSSL-BMS) is a nanoformulation capable of crossing the blood-brain barrier, created by encapsulating Betamethasone hemisuccinate in PEGylated liposomes. By leveraging the enhanced permeability and retention effect of liposomes, Betamethasone succinate effectively delivers potent glucocorticoids to inflammatory sites. It inhibits the secretion of pro-inflammatory cytokines, such as TNF-α and IL-6, while maintaining the levels of the anti-inflammatory cytokine TGF-β. This compound is useful for researching arthritis and cerebral malaria.

Bis(2,5-dioxopyrrolidin-1-yl) succinate is a PROTAC linker utilized in the synthesis of PROTAC molecules.

Di-tert-butyl succinate is a PROTAC linker used in the synthesis of PROTAC molecules.

Rabacfosadine succinate is the acyclic nucleoside phosphonate PMEG double prodrug.